Insider Transactions in Q1 2021 at Decibel Therapeutics, Inc. (DBTX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2021
|
Adveq Technology Ix S.C.S. Schroder > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,048,656
+50.0%
|
-
|
|
Feb 17
2021
|
Neil Exter Director |
BUY
Conversion of derivative security
|
Indirect |
3,092,516
+18.14%
|
-
|
|
Feb 17
2021
|
Peter A. Thompson Director |
BUY
Open market or private purchase
|
Indirect |
1,666,666
+30.52%
|
$29,999,988
$18.0 P/Share
|
|
Feb 17
2021
|
Peter A. Thompson Director |
BUY
Conversion of derivative security
|
Indirect |
3,278,526
+50.0%
|
-
|
|
Feb 17
2021
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
575,000
+33.89%
|
$10,350,000
$18.0 P/Share
|
|
Feb 17
2021
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
546,421
+50.0%
|
-
|
|
Feb 17
2021
|
Matthew Foy Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+11.25%
|
$2,700,000
$18.0 P/Share
|
|
Feb 17
2021
|
Matthew Foy Director |
BUY
Conversion of derivative security
|
Indirect |
1,033,663
+33.34%
|
-
|
|
Feb 17
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,666,666
+30.52%
|
$29,999,988
$18.0 P/Share
|
|
Feb 17
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
3,278,526
+50.0%
|
-
|
|
Feb 17
2021
|
Glaxosmithkline PLC Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+11.25%
|
$2,700,000
$18.0 P/Share
|
|
Feb 17
2021
|
Glaxosmithkline PLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,033,663
+33.34%
|
-
|
|
Feb 17
2021
|
Longevity Fund 2 LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
79,143
+50.0%
|
-
|
|
Feb 17
2021
|
Regeneron Pharmaceuticals, Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,097,314
+50.0%
|
-
|
|
Feb 17
2021
|
Gv 2016 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
321,978
+50.0%
|
-
|
|
Feb 17
2021
|
Gv 2017 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
494,649
+50.0%
|
-
|
|
Feb 17
2021
|
Gv 2019 Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
819,631
+50.0%
|
-
|